Gufic Biosciences Limited
NSE:GUFICBIO.NS
485.45 (INR) • At close November 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) INR.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 8,066.657 | 6,906.208 | 7,791.556 | 4,876.986 | 3,577.512 | 3,507.696 | 3,009.644 | 2,492.685 | 2,021.988 | 1,515.516 | 1,230.112 | 1,001.441 | 835.651 | 715.783 | 628.864 | 516.841 | 540.943 |
Cost of Revenue
| 5,165.387 | 3,318.204 | 4,296.313 | 2,577.677 | 1,805.326 | 1,818.224 | 1,432.412 | 1,231.656 | 1,044.683 | 828.853 | 674.719 | 519.595 | 449.602 | 369.404 | 340.504 | 281.079 | 334.834 |
Gross Profit
| 2,901.27 | 3,588.004 | 3,495.243 | 2,299.309 | 1,772.186 | 1,689.472 | 1,577.232 | 1,261.029 | 977.305 | 686.663 | 555.393 | 481.846 | 386.049 | 346.379 | 288.36 | 235.761 | 206.11 |
Gross Profit Ratio
| 0.36 | 0.52 | 0.449 | 0.471 | 0.495 | 0.482 | 0.524 | 0.506 | 0.483 | 0.453 | 0.451 | 0.481 | 0.462 | 0.484 | 0.459 | 0.456 | 0.381 |
Reseach & Development Expenses
| 54.125 | 51.859 | 44.286 | 20.989 | 20.007 | 20.775 | 52.882 | 15.286 | 6.776 | 2.581 | 7.313 | 0 | 0 | 0 | 0 | 0 | 0 |
General & Administrative Expenses
| 1,110.963 | 880.686 | 142.614 | 92.029 | 60.495 | 67.788 | 60.509 | 67.101 | 59.55 | 38.577 | 26.459 | 17.761 | 0 | 0 | 0 | 0 | 0 |
Selling & Marketing Expenses
| 21.225 | 59.562 | 33.441 | 18.574 | 37.026 | 17.312 | 13.236 | 0.965 | 5.733 | 7.461 | 71.213 | 138.545 | 0 | 0 | 0 | 0 | 0 |
SG&A
| 1,612.728 | 940.248 | 176.055 | 110.603 | 97.521 | 85.1 | 73.745 | 68.066 | 65.283 | 46.038 | 97.672 | 156.306 | 0 | 0 | 0 | 0 | 0 |
Other Expenses
| 21.772 | 25.739 | 3.983 | 2.744 | 28.095 | 21.414 | 18.379 | 0.14 | 1.85 | 2.533 | 1.997 | 0.293 | 2.499 | 301.583 | 249.286 | 200.879 | 171.915 |
Operating Expenses
| 1,612.728 | 2,464.301 | 2,208.792 | 1,617.83 | 1,396.363 | 1,269.105 | 1,238.579 | 1,026.348 | 812.064 | 578.037 | 458.417 | 386.974 | 333.718 | 301.583 | 249.286 | 200.879 | 171.915 |
Operating Income
| 1,288.542 | 1,153.309 | 1,290.999 | 676.53 | 385.399 | 413.437 | 338.653 | 173.997 | 108.306 | 60.645 | 57.601 | 49.703 | 26.176 | 23.704 | 16.936 | 17.176 | 15.611 |
Operating Income Ratio
| 0.16 | 0.167 | 0.166 | 0.139 | 0.108 | 0.118 | 0.113 | 0.07 | 0.054 | 0.04 | 0.047 | 0.05 | 0.031 | 0.033 | 0.027 | 0.033 | 0.029 |
Total Other Income Expenses Net
| -131.827 | -86.1 | -22.616 | -99.415 | -84.137 | -59.947 | -43.246 | -54.507 | -52.655 | -38.892 | -32.904 | -34.44 | -22.63 | -21.091 | -22.138 | -17.706 | -18.584 |
Income Before Tax
| 1,156.715 | 1,067.209 | 1,268.383 | 577.115 | 303.301 | 353.491 | 295.407 | 180.174 | 111.91 | 65.259 | 62.734 | 52.631 | 29.701 | 23.704 | 16.936 | 17.176 | 15.611 |
Income Before Tax Ratio
| 0.143 | 0.155 | 0.163 | 0.118 | 0.085 | 0.101 | 0.098 | 0.072 | 0.055 | 0.043 | 0.051 | 0.053 | 0.036 | 0.033 | 0.027 | 0.033 | 0.029 |
Income Tax Expense
| 295.36 | 270.161 | 309.982 | 134.799 | 74.734 | 134.084 | 135.19 | 66.039 | 38.667 | 23.685 | 20.091 | 19.339 | 14.43 | 9.064 | 4.658 | 8.812 | 6.84 |
Net Income
| 861.355 | 797.048 | 958.401 | 442.316 | 226.879 | 219.407 | 160.217 | 114.135 | 73.243 | 41.574 | 42.643 | 33.292 | 15.271 | 14.641 | 12.278 | 8.364 | 8.771 |
Net Income Ratio
| 0.107 | 0.115 | 0.123 | 0.091 | 0.063 | 0.063 | 0.053 | 0.046 | 0.036 | 0.027 | 0.035 | 0.033 | 0.018 | 0.02 | 0.02 | 0.016 | 0.016 |
EPS
| 8.74 | 8.22 | 9.89 | 4.56 | 2.34 | 2.82 | 2.06 | 1.17 | 0.95 | 0.54 | 0.55 | 0.43 | 0.2 | 0.19 | 0.16 | 0.11 | 0.11 |
EPS Diluted
| 8.74 | 8.22 | 9.89 | 4.56 | 2.34 | 2.82 | 2.06 | 1.17 | 0.95 | 0.54 | 0.55 | 0.43 | 0.2 | 0.19 | 0.16 | 0.11 | 0.11 |
EBITDA
| 1,458.714 | 1,372.252 | 1,473.912 | 857.474 | 506.668 | 499.357 | 409.233 | 279.075 | 202.146 | 148.009 | 126.315 | 107.362 | 71.143 | 62.862 | 55.699 | 43.535 | 52.231 |
EBITDA Ratio
| 0.181 | 0.199 | 0.189 | 0.176 | 0.142 | 0.142 | 0.136 | 0.112 | 0.1 | 0.098 | 0.103 | 0.107 | 0.085 | 0.088 | 0.089 | 0.084 | 0.097 |